The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored
Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Capsules USP are administered, usually in divided doses, two to four times a day. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient's needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.
Oral Administration
Initial dosage of 10 mg twice daily is recommended, although in severely disturbed patients initial dosage up to a total of 50 mg daily may be desirable. Dosage should then be increased fairly rapidly over the first seven to ten days until there is effective control of symptoms of schizophrenia. The usual therapeutic and maintenance range is 60 mg to 100 mg daily. However, as with other drugs used to treat schizophrenia, some patients respond to lower dosage and others require higher dosage for optimal benefit. Daily dosage higher than 250 mg is not recommended.
Maintenance Therapy
For maintenance therapy, dosage should be reduced to the lowest level compatible with symptom control; many patients have been maintained satisfactorily at dosages in the range of 20 to 60 mg daily.
How supplied
Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Capsules USP are available in the following strengths:
Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 6.8 mg equivalent to 5 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and cap, printed with Watson 369 on one half and 5 mg on the other, are supplied in bottles of 100.
Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 13.6 mg equivalent to 10 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and yellow cap, printed with Watson 370 on one half and 10 mg on the other, are supplied in bottles of 100.
Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 34.0 mg equivalent to 25 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and green cap, printed with Watson 371 on one half and 25 mg on the other, are supplied in bottles of 100.
Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 68.1 mg equivalent to 50 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and blue cap, printed with Watson 372 on one half and 50 mg on the other, are supplied in bottles of 100.
Store at 20°-25°C (68°-77°F). Dispense in a tight, child-resistant container.
Watson Laboratories, Inc. Corona, CA 92880, USA. Revised: March 2008. FDA Rev date: 12/02/02
What other drugs will affect Loxapina [Inn-Spanish]?
Taking Loxapina [Inn-Spanish] with other drugs that make you sleepy or slow your breathing can increase these effects. Ask your doctor before taking Loxapina [Inn-Spanish] with a sleeping pill, narcotic pain medicine, muscle relaxer, or medicine for anxiety, depression, or seizures.
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Loxapina [Inn-Spanish], especially:
bladder or urinary medicines such as darifenacin, tolterodine, solifenacin;
bronchodilators such as ipratropium or tiotropium;
cold or allergy medicine that contains an antihistamine;
medication for Parkinson's disease; or
medication to treat excess stomach acid, stomach ulcer, motion sickness, or irritable bowel syndrome.
This list is not complete. Other drugs may interact with Loxapina [Inn-Spanish], including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Loxapina [Inn-Spanish] interactions
Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Loxapina [Inn-Spanish], it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored
There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) and lorazepam.
The risk of using Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) and CNS-active drugs is required.
References
DailyMed. "LOXAPINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
FDA/SPL Indexing Data. "LER583670J: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Loxapina [Inn-Spanish] are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Loxapina [Inn-Spanish]. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported frequency of use
No survey data has been collected yet
Consumer reported doses
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!
